| INTRODUCTION
Vitamin K antagonists (VKAs) have a narrow therapeutic window, several food and drug interactions and a variable anticoagulant response, which explain the need for periodical anticoagulation monitoring and dose adjustment. 1 As VKAs inhibit the synthesis of vitamin K-dependent coagulation factors (factors II, VII, IX and X), they are monitored using laboratory tests that assess the extrinsic pathway of the coagulation cascade. The prothrombin time (PT) measures the time to clot formation of citrated plasma, after recalcification and addition of thromboplastin to trigger coagulation, and is usually expressed as international normalized ratio (INR). The WHO-recommended method for PT testing in relation to VKA therapy is the manual tilttube technique, 2 but currently most PT determinations are performed using automated coagulation analysers, such as photo-optical or electromechanical coagulometers. Furthermore, in the last two decades, several portable coagulometers, also known as point-of-care (POC) devices, have been developed for the self-care of patients prescribed with VKAs. 3 More recently, we saw the advent of global coagulation assays, such as thrombin generation, which may have the potential to better evaluate all phases of coagulation.
4
Several studies indicated an excellent correlation between photooptical and electromechanical coagulation analysers, 5, 6 while the comparison between POC and laboratory or manual INRs showed a certain variability in the results, with potential clinical disagreement and differences in VKA dosing. [7] [8] [9] [10] However, it is not known which test actually correlates better with the overall blood coagulation potential, because these three INR methods have never been compared simultaneously with global coagulation assays.
The aim of this study was to assess the agreement of three different INR assays, compared with thrombin generation, in patients on VKA treatment.
| MATERIAL AND METHODS

| Study population
Consecutive adult patients attending the Anticoagulation Clinic at
Mater Dei Hospital (in Msida, Malta) for warfarin monitoring were The study was reviewed and approved by the University of Malta
Research and Ethics Committee, and written informed consent was obtained from all patients before inclusion.
| Sample collection and tests performed
| Laboratory INR
From each patient, one venous blood sample was collected using a 10-mL syringe and a 21G needle, to fill in three coagulation tubes, each containing 2 mL of whole blood and sodium citrate 0.109M/3.2% (Vacuette, Greiner Bio-One). One tube was processed according to the standard system at Mater Dei Hospital at the time of this study. This tube was centrifuged for 10 minutes at 2500 g and plasma was analysed using a photo-optical clot detection system (Sysmex CS-2100i or CA-1500, Siemens Healthcare Diagnostics) and human recombinant thromboplastin (Dade Innovin; Siemens Healthcare Diagnostics Products GmbH). We had previously tested with both Sysmex analysers 33 samples with various INRs, ranging from 0.9 to 4.45, and found no statistical difference in the PT and the INR between the two analysers (data not shown).
The two remaining tubes underwent double centrifugation (2500 g for 10 min twice) with plasma separation, to obtain platelet poor plasma (PPP) within a 2-hour time frame from phlebotomy. 
| Thrombin generation
Frozen aliquots were shipped to the Coagulation Laboratory at the Royal Hallamshire Hospital (in Sheffield, United Kingdom) in dry ice. Thrombin generation was performed using the calibrated automated thrombogram (CAT), according to the method described by Hemker et al.. Data analysis was performed using the statistical software STATA SE 12 (StataCorp LP, College Station, TX, USA). Two-tailed P values<.05 were considered statistically significant.
| RESULTS
| Study population
Sixty patients were enrolled in this study. Mean (SD) age was 68.5 (11.5) years, and 26 (43.3%) were males. The most common indications for warfarin treatment were atrial fibrillation (63.3%) and venous thromboembolism (26.7%), followed by mechanical heart valve replacement (8.4%). The majority of patients (73.3%) were on oral anticoagulant treatment for more than a year. The current median (IQR) dose of warfarin was 4 (3-5) mg. Comorbidities and concomitant medications in our population are summarized in Table 1 . None of these patients had known antiphospholipid syndrome.
| Different INR methodologies
Using the standard laboratory instrumentation in our Coagulation 
| Thrombin generation
The intra-assay coefficient of variation (CV) of thrombin generation was 4.3%. The interassay CV was 13.7% for the normal QC and 6.8%
for the warfarin QC.
Thrombin generation results are summarized in vs. 67.0%, P=.77, respectively). There was no difference in the other parameters of the thrombin generation curve, as reported in Table 3 . plots, is reported in Figure 3 . 
| Correlation between thrombin generation and different INR methodologies
| Comparison between INRs
| DISCUSSION
To the best of our knowledge, this is the first time that three different measurements were performed by a trained scientist, and our results might not be generalizable, for example, to all patients performing INR self-testing.
In conclusion, our study showed that the relationship between INR results and thrombin generation does not differ depending on the assay used for INR measurement. Despite not being generally considered as the "gold standard", the POC INR showed one of the highest correlation coefficients with thrombin generation, therefore confirming the POC devices as an accurate and valid alternative to laboratory INR in VKA patients.
